Cervical cancer is largely preventable with timely vaccination and screening. Early awareness can save thousands of lives ...

Merck & Co. is adding yet another immuno-oncology first under Keytruda’s belt. But the breadth of the win comes out less than ideal. The FDA has backed Keytruda’s use alongside chemotherapy, with or ...

Final phase 3 trial results confirm a survival benefit with the immunotherapy cemiplimab (Libtayo) when used for the second-line treatment of recurrent or metastatic cervical cancer. They come from ...

HPV is often considered a taboo subject. Although most of us will be exposed human papillomavirus (HPV) at some point in our lives, it remains widely misunderstood.Receiving a positive HPV result can ...

Investigators examined cervical cancer screening guideline adherence among a nationally representative commercially insured cohort in the US to identify factors and modalities associated with ...

Results from a phase 3 trial showing prolonged survival with the immunotherapy cemiplimab (Libtayo) in the second-line treatment of recurrent or metastatic cervical cancer are being hailed as ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA granted priority review to ...

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo ® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...